Related Experiment Video
Updated: May 27, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Targeting PDGFR-β in Cholangiocarcinoma
Christian D Fingas1, Joachim C Mertens, Nataliya Razumilava
1Mayo Clinic College of Medicine, Rochester, MN, USA.
Summary
Targeting PDGFR-β in cholangiocarcinoma (CCA) restores cancer cell sensitivity to apoptosis. This approach showed therapeutic potential in preclinical models, offering a new strategy for CCA treatment.
Area of Science:
- Oncology
- Cancer Biology
- Drug Discovery
Background:
- Cholangiocarcinomas (CCA) are desmoplastic tumors with a microenvironment rich in myofibroblasts (MFBs).
- MFB-derived PDGF-BB signaling promotes CCA cell resistance to apoptosis.
- Targeting PDGFR-β, the receptor for PDGF-BB, is a potential therapeutic strategy for CCA.
Purpose of the Study:
- To investigate the role of PDGFR-β inhibition in restoring CCA cell sensitivity to apoptotic stimuli.
- To evaluate the therapeutic efficacy of PDGFR-β targeting in vitro and in vivo.
Main Methods:
- Utilized human CCA samples, CCA cell lines (KMCH-1, HUCCT-1), and MFBs (LX-2).
- Employed shRNA to knock down PDGFR-β (shPDGFR-β-KMCH-1).
- Conducted in vivo experiments using a syngeneic rat orthotopic CCA model and tyrosine kinase inhibitors (imatinib mesylate, linifanib).
Main Results:
- PDGF-BB, but not CTGF, from MFBs attenuated TRAIL-induced apoptosis in CCA cells.
- MFB-mediated cytoprotection against TRAIL was abrogated by PDGFR-β inhibition (imatinib, linifanib) or knockdown.
- In vivo, imatinib mesylate increased CCA cell apoptosis and reduced tumor growth in a rat model.
Conclusions:
- Inhibition of PDGFR-β sensitizes cholangiocarcinoma cells to apoptotic stimuli.
- Targeting PDGFR-β demonstrates therapeutic potential in preclinical CCA models.
